Trending With Impact: Reversing Radiation Necrosis with Monoclonal Antibodies

Posted by

Oncotarget

Oncotarget published this trending case report on March 29, 2022 in Volume 13, entitled, "Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma" by researchers from the Department of Radiation Oncology, Duke University Medical Center, Durham, NC; Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC; Department of Pathology, Duke University Medical Center, Durham, NC; Department of Neurology, UC San Diego Health, San Diego, CA; Department of Pharmacy, Duke University Medical Center, Durham, NC; Virginia Oncology Associates, Norfolk, VA; Department of Neurosurgery, Duke University Medical Center, Durham, NC. Department of Neurology, Duke University Medical Center, Durham, NC. DOI - https://doi.org/10.18632/oncotarget.28222 Correspondence to - Eugene J. Vaios - eugene.vaios@duke.edu Abstract Importance: Radiation necrosis (RN) is a rare but serious adverse effect following treatment with radiation therapy. No standard of care exists for the management of RN, and efforts to prevent and treat RN are limited by a lack of insight into the pathomechanics and molecular drivers of RN. This case series describes the outcomes of treatment with bevacizumab (BV) in two primary CNS lymphoma (PCNSL) patients who developed symptomatic biopsy-proven RN after whole brain radiation (WBRT) with a stereotactic radiosurgery (SRS) boost. Observations: Patient 1 is a 52 year-old female with PCNSL treated with WBRT followed by an SRS boost. She developed symptomatic biopsy-proven RN, and initial treatment with tocopherol and pentoxifylline was unsuccessful. A 100% clinical and radiographic response was achieved with 4 cycles of BV. Patient 2, a 48 year-old male with PCNSL, presented with seizures and biopsy-proven RN after radiation therapy. Initial empiric treatment with tocopherol and pentoxifylline was unsuccessful. A 100% clinical and radiographic response was achieved with 3 cycles of BV. Conclusions and Relevance: Monitoring for RN in patients with PCNSL treated with radiation therapy is warranted. BV is an efficacious treatment and a viable alternative to corticosteroids or surgical intervention. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28222 Keywords - radiation necrosis, brain tumor, primary CNS lymphoma, stereotactic radiosurgery, bevacizumab About Oncotarget Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957